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(US$20,888). RESULTS: The total cost of six-months treatment with rivaroxaban 
was US$89 and US$96* higher than warfarin. Increased drug cost (US$356) 
associated with rivaroxaban, was offset by reduced monitoring costs (US$239). 
Moreover, rivaroxaban was associated with LY increments of 0.006 and 0.026* 
years and QALY increments of 0.005 and 0.022* years. The ICERs were US$16,227 
and US$3,488* per LY gained and US$17,928 and US$4,056* per QALY gained. 
Sensitivity analysis showed that ICER value was sensitive only to the frequency 
of monitoring (between two to six-times a year) in warfarin patients. 
CONCLUSIONS: Rivaoxaban is cost-effective in the Turkish setting for the acute 
treatment of DVT patients, with ICERs below accepted WTP threshold across a 
range of conservative scenarios. * all pairs of figures correspond to 5-years and life-
time horizon, respectively.  
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OBJECTIVES: To build a flexible pharmacoeconomic model for early-stage 
analysis of interventions to prevent major adverse cardiovascular events 
(MACE=non fatal myocardial infarction (MI) and stroke, and cardiovascular 
death). METHODS: A literature search of cost-effectiveness models of 
cardiovascular disease interventions was conducted. Two models, one for heart 
disease and one for stroke, were selected as the framework (e.g., health states 
and transitions) for the development of an acute coronary syndrome (ACS) 
microsimulation model. Major parameter inputs were extracted from published 
literature. UK-based exploratory analyses using health state costs from the 
National Health System (NHS) reference costs and drug costs from the NHS 
October 2012 Electronic Drug Tariff, varied first-year risk of subsequent MACE 
events from 8-12%; and treatment efficacy (defined as a relative risk reduction 
(RRR)) from 15-25%. The base case treatment comparator was defined as 
standard of care (SoC) consistent with guidelines on secondary prevention of MI, 
including antihypertensive medications, aspirin, a statin, and one year of 
clopidogrel after each ACS event. New treatments can be added to, or substituted 
in the SoC. Age, gender, and patient history were varied for 10,000 individual 
patients simulated over specified timeframes. RESULTS: The model estimates a 
range of 15 to 39 MACE avoided per thousand patients in one year for a 15% RRR 
with an 8% background MACE rate versus a 25% RRR with a 12% background 
MACE rate, respectively. Assuming a £20,000/QALY willingness to pay in the UK, 
estimated lifetime incremental costs and QALYs predict the net benefit to be 
£1,371 for a point estimate of 20% RRR of a 10% background MACE rate. 
CONCLUSIONS: Early cost-effectiveness analyses using feasible RRRs in typical 
background MACE rates seen in ACS populations can be cost effective. Validation 
of this model framework can lead to more robust conclusions.  
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OBJECTIVES: Venous thromboembolism (VTE) causes significant impact on 
morbidity/mortality and economic burden to health systems. For preventing VTE 
in hip fracture/arthroplasty, the American College of Chest Physicians Practice 
Guidelines recommends the use of antithrombotic agents, such as fondaparinux 
and low-molecular weight heparin (LMWH). We present a cost-effectiveness 
analysis of fondaparinux versus enoxaparin for the prevention of VTE in hip 
surgery in Brazil. METHODS: A decision model was developed with a 180-day 
post-surgery horizon for the comparison of fondaparinux versus enoxaparin, 
both administered during hospitalization (average eight days) for the prophylaxis 
of VTE in hip surgery. Thromboembolic event and major bleeding probabilities 
were derived from three major published randomized clinical trials comparing 
fondaparinux and enoxaparin (N>6,000). Costs were calculated using 
microcosting technique in search for hip surgery and thrombotic/hemorrhagic 
complications reimbursed from the public Brazilian Unified Health System 
Database (DATASUS) in June 2012. Drug prices for antithrombotic prophylaxis 
were extracted from the Health Prices Database (BPS) in 2012 (1BRZ=0.52USD). 
RESULTS: VTE was observed in 5.9% versus 11.5% of patients with fondaparinux 
and enoxaparin, respectively (relative risk reduction=48.8%). Major bleeding 
(leading to death, reoperation or in critical sites) were similar in both groups, 
although bleeding with index >2 were more frequent in fondaparinux (2.4% 
versus 1.7%). Cost-effectiveness data showed fondaparinux was dominant over 
enoxaparin (i.e., reduced mortality at lower costs). There was an increment of 
three deaths per 1,000 patients by using enoxaparin instead of fondaparinux. 
Fondaparinux reported cost savings of BRZ16.53 per patient treated. Influence 
analysis showed that the incremental deaths and costs of enoxaparin were 
largely related to the higher incidence of thrombotic complications. 
CONCLUSIONS: Fondaparinux was found to be a cost-effective option under the 
Brazilian Public Health System perspective for the prophylaxis of VTE, resulting 
in lower mortality incidence at a reduced budget impact.  
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OBJECTIVES: In the management of atrial fibrillation (AF), warfarin has been the 
anticoagulant of choice for preventing thrombotic complications, however, its 
need for regular blood test monitoring has led to the development of alternatives 
such as dabigatran. In order to address the variability and uncertainties in cost-
effectiveness and budget impact across jurisdictions, a systematic review of 
economic analyses was conducted. METHODS: A systematic review was 
conducted of economic evaluations published to November 2011 evaluating the 
cost-effectiveness of dabigatran versus warfarin for stroke prevention in AF. 
Databases searched included Ovid MEDLINE, EMBASE, the Cochrane Library and 
PubMed. The grey literature was also searched for relevant articles. For the 
purpose of a qualitative synthesis, details on the study design, data sources, cost 
effectiveness results (i.e. incremental cost effectiveness ratios (ICER)) were 
abstracted. Key factors influencing the cost-effectiveness of dabigatran 
compared with warfarin across different countries and health systems were 
identified. RESULTS: Seven economic evaluations comparing dabigatran and 
warfarin from four countries were identified. Costs, QALYs and ICERS were 
reported in all but one study. ICERs for dabigatran compared to warfarin ranged 
from £4,879.17 to $152,142.86 US, depending on the dabigatran dose and 
currency. Variations in ICERs occurred despite the fact that the efficacy and 
hemorrhage data were obtained from the same source, the RE-LY trial. Key 
factors identified between the models for variability in the results included 
differences in the costs of managing AF across countries; assumptions regarding 
warfarin monitoring frequency and costs, and INR control (trial-like or real-world 
setting); incorporation of baseline risk in relative rates of adverse events; and the 
costs of treating dabigatran-related hemorrhages without an antidote. 
CONCLUSIONS: Economic analyses for dabigatran versus warfarin have 
produced widely varying results. Real world effectiveness and safety data, 
including warfarin management practices, are useful to inform cost-
effectiveness in practice.  
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OBJECTIVES: . Due to the aging of the population, musculoskeletal diseases, 
particularly articular diseases and fragility fractures, have been constantly 
increasing. For this reason, total hip replacement (THR) and total knee 
replacement (TKR) have also increased. These procedures impact the quality of 
life and imply high risk of venous thromboembolism (VeT). VeT events have a 
high mortality in the elderly, 21% on hospitalized patients and up to 39% one 
year after the surgery. Prophylaxis for VeT is as a major strategy to minimize the 
consequences on patients undergoing TKR and THR. The aim of this study was to 
assess the cost-effectiveness (CE) of apixaban against dabigatran, rivaroxaban, 
fondaparinux, and enoxaparin for VeT prevention on these patients in 
Guatemala, from the private health care perspective. METHODS: . A simulated 
cohort of 1,000 patients subjected to THR/TKR entered a decision-tree model to 
compare costs and effectiveness of apixaban (2.5 mg/12 hours), dabigatran (220 
mg/day), rivaroxaban (10 mg/day), fondaparinux (2.5 mg/day) and enoxaparin (30 
mg/12 hours). Effectiveness measures were: total VeT events, bleeding rates and 
deaths. The model used a 5 year time horizon and only direct medical costs were 
considered (inpatient costs, medication expenses, adverse events, tests). 
Effectiveness and epidemiologic data were retrieved from published literature. 
Local costs (2012 US$) were gathered from the 3 private hospitals of Guatemala 
official databases. RESULTS: . The total VeT events were 69 for Apixaban, 55 for 
Rivaroxaban, 112 for Dabigatran, 86 for Enoxaparin and 45 for Fondoparinux. The 
estimated bleeds were 71 (Apixaban), 85 (Rivaroxaban), 85 (Dabigatran), 73 
(Enoxaparin) and 31 (Fondaparinux). Apixaban dominated enoxaparin and 
dabigatran while rivaroxaban and fondaparinux had an ICER of 
US$104,177/QALY and US$103,933/QALY, respectively. In the acceptability 
curves, Apixaban appeared with the highest probability of being cost-effective. 
CONCLUSIONS: . Apixaban resulted as the cost-effective therapy for VeT 
prevention for adult patients in Costa Rica.  
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OBJECTIVES: Aortic stenosis is the most common valvular heart disease in the 
elderly - it is estimated that its prevalence is up to 5% in individuals over 75 
years. Its standard treatment is surgical valve replacement; however the surgical 
risk is very high for patients with advanced age and with the association of 
comorbidities. Thus, a significant proportion of patients become ineligible for 
this therapy. Treatment with transcatheter aortic valve implantation (TAVI) is a 
therapy with potentially lower risk peri-procedure and has been used as a 
therapeutic option in this group of patients considered inoperable. The aim of 
this study was to develop a cost-effectiveness analysis of the SAPIEN® valve 
implantation in patients with severe aortic stenosis who are not eligible for 
surgical treatment. METHODS: A Markov model was developed to compare the 
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SAPIEN® transcatheter implantation therapy versus drug treatment with or 
without aortic balloon valvoplasty. The outcomes used were effectiveness (as 
measured by clinical outcomes chance of successful implantation procedure and 
survival) and safety. The results were expressed as the reason of incremental 
cost-effectiveness ratio (ICER) per years saved and years free from serious 
adverse events. Probabilistic sensitivity analysis was performed on the main 
parameters of the model. RESULTS: Compared with medical therapy with or 
without aortic balloon valvuloplasty, the employment of the SAPIEN® valve 
presents safety in the procedure, increased survival and compatible ICER – US$ 
40.000/life of year saved. CONCLUSIONS: The use of SAPIEN® transcatheter 
implantation results in improved survival and functional improvement in 
patients with low risk of serious adverse events, and demonstrates a cost-
effectiveness profile when compared to other technologies already incorporated 
by the Brazilian public health system.  
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OBJECTIVES: To evaluate the cost-effectiveness of apixaban compared to 
enoxaparin, rivaroxaban and dabigatran in venous thromboembolism prevention 
(VTEp) in patients undergoing elective total knee or hip replacement (TKR, THR) 
from the private payer’s perspective in Colombia. METHODS: An economic 
model, including both a decision tree component and a Markov model was 
created to compare apixaban 5mg/day, enoxaparin 40mg/day, dabigatran 
220mg/day and rivaroxaban 10mg/day. The decision tree considers potential 
VTE, bleeding, death events as well as no-events which occur over the short-
term and lends itself to model the prophylactic and post-prophylactic phases 
over the first 90 days post-surgery. Events that occur over the long term are 
modeled using a Markov structure, which provides the option to simulate events 
such as recurrent VTE and post-thrombotic syndrome. The model relies upon the 
results from a mixed treatment comparison study for key efficacy and safety 
inputs, information from published literature for unit cost and utility data, and 
Colombian cost and patterns of care study for resource use and event costs. 
Results are reported as cost per quality-adjusted life years gained (QALY’s) and 
life years gained (LYG) over a prophylaxis + five-year time horizon. A discount 
rate of 3.5% was used for both costs and outcomes. RESULTS: Results indicate 
that the use of apixaban is dominant compared to enoxaparin and dabigatran in 
the overall population for THR and TKR (less number of VTE events, total bleeds 
and deaths which generated higher number QALYs and lower overall costs). 
When compared to rivaroxaban the model results show similar long-term gains 
in QALY’s and LYG for apixaban, as well as similar costs -showing small savings 
for apixaban mainly due to lower bleeding costs. CONCLUSIONS: Apixaban is a 
cost-effective alternative in preventing VTE in patients undergoing THR or TKR 
in Colombian private setting.  
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COST-EFFECTIVENESS OF THROMBOLYSIS FOR MYOCARDIAL INFARCTION 
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OBJECTIVES: Most patients with myocardial infarction in Colombia are treated 
with streptokynase, despite tenecteplase being recognized as more effective. Our 
objective was to evaluate the cost-effectiveness and cost-utility of tenecteplase, 
compared with streptokinase, in the treatment of ST elevation myocardial 
infarction. METHODS: We designed a decision tree model, from the perspective 
of the Colombian health system. We calculated quality adjusted life years (QALY) 
gained (using data Tuft's registry), as well as cost per death, and cost per major 
outcome averted (death, stroke, severe heart failure). The costs were estimated 
in Colombian pesos for 2012 (Exchange rate 1US$=COP$1785) using national tariff 
manuals (Social Security 2001 with inflation adjustment) and resource use 
obtained from our local university hospital, validated by national expert panel. 
We performed a probabilistic and deterministic sensitivity analysis. RESULTS: 
The average total cost for a tenecteplase treated patient was US$1456. The cost 
per incremental QALY gained with tenecteplase was US$14,447; US$95,302 per 
death averted, and US$38,578 for major outcome averted. The average total cost 
for the treatment of acute phase of all myocardial infarctions for 2012 was 
estimated in US$728,000. Monte Carlo simulation acceptability curve showed 
that in 85% of the trials the result would be cost-effective, assuming a 
willingness to pay of up to three times the per capita gross domestic product 
(Colombia's per capita GDP is US$6723). If the cost of tenecteplase were lowered 
from US$2066 to US$389 the cost per QALY would reach the one per capita GDP 
threshold. CONCLUSIONS: Our results suggest that tenecteplase is cost effective 
if we accept the three-times per capita GDP threshold.  
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OBJECTIVES: The multi-centered, double-blind, randomized PLATO trial on 18,624 
patients from 43 countries has demonstrated that ticagrelor was superior in 
reducing the rates of cardiovascular mortality, myocardial infarction (MI), or stroke 
among patients with acute coronary syndrome (ACS) compared to clopidogrel but 
without a significant increase in major bleedings. This study aimed to evaluate the 
long-term cost-effectiveness of ticagrelor plus acetylsalicylic acid (ASA) versus 
clopidogrel plus ASA in ACS patients in Hong Kong (HK) from a public hospital’s 
perspective. METHODS: A two-phase state-transition Markov model was developed 
to estimate the long-term economic and health outcomes measured as quality-
adjusted life years (QALYs). PLATO data were utilized to estimate patients’ resource 
use (incl. hospitalization bed days, investigations, interventions and blood products), 
rate of cardiovascular events (i.e. MI and stroke) and QALYs for the first year. 
Outcomes from the second year onwards were extrapolated using results from the 
first year. Direct health care costs were HK-specific and utility data were adopted 
from published literature. Time horizons were set at 1 year, 5 years and patients’ 
lifetime. All costs which were presented as 2012 figures and effectiveness were both 
discounted at 3% per annum. A series of one-way and multi-way sensitivity 
analyses were performed to test model robustness. RESULTS: Over a lifetime 
horizon, the use of ticagrelor led to improved clinical outcome with a discounted 
survival of 13.08 QALYs per patient in the ticagrelor treatment group compared to 
12.91 in the clopidogrel treatment group. Despite its higher daily cost, ticagrelor was 
predicted to significantly reduce resource utilization by HKD6,348 (USD814, 
1USD=7.8HKD) and stroke treatment cost by HKD45,226 (USD5,798) per patient 
which can be translated into a heavy public health care expenditure. 
CONCLUSIONS: The treatment of ACS patients with lifetime use of ticagrelor is 
considered cost-saving compared with clopidogrel from a public health care 
provider perspective in HK.  
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OBJECTIVES: Atrial fibrillation (AF) is a chronic, progressive disease 
characterized by uncoordinated atrial activation involving a rapid and irregular 
heartbeat. Its prevalence has been increasing worldwide. Antiarrhythmic drug 
therapy is a commonly-used treatment for paroxysmal AF, and catheter ablation 
has become an important treatment alternative. The purpose of this study was 
to assess the cost-effectiveness of catheter ablation compared to antiarrhythmic 
drug (AAD) therapy for the treatment of paroxysmal AF in Canada. METHODS: A 
simulation model was developed for a hypothetical cohort of 55-year-old 
patients with drug-refractory paroxysmal AF and a low stroke risk. The first year 
was modeled with a decision tree. Years 2 and beyond were modeled with a 
Markov simulation. The model treatment arms were catheter ablation and AAD 
mono-therapy. The model was created to assess costs and quality-adjusted life-
years over a lifetime horizon. Clinical efficacy of catheter ablation and AAD 
therapy were modeled based on the results of a recently-published randomized 
controlled trial (Wilber et al., 2010). Utilities and state transition probabilities 
were drawn from the published literature. Costs were specific to Canada. 
RESULTS: The incremental cost-effectiveness ratio for catheter ablation versus 
AAD therapy ranged from CAD$10,000 to a dominant strategy (cost less and is 
more effective) per quality-adjusted life-year. Over a lifetime horizon, the 
quality-adjusted life expectancy ranged from 11.25 to 11.75 years for catheter 
ablation compared to 10.75 to 11.25 years for AAD therapy. The results were 
robust in sensitivity analysis. Results were most sensitive to ablation costs, 
probability of successful ablation treatment, and probability of revision to AF. 
CONCLUSIONS: Catheter ablation appears to be cost-effective compared to AAD 
therapy among patients who had drug refractory paroxysmal AF in the Canadian 
population when using a cost-effectiveness threshold of CAD$50,000. Further 
research is necessary to understand the effect of newly approved OAC therapies. 
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OBJECTIVES: To evaluate the cost-effectiveness of new oral anticoagulants 
(apixaban, dabigatran and rivaroxaban) compared relative to each other and 
relative to warfarin for stroke prevention in patients with atrial fibrillation. 
METHODS: We developed a decision analytic model, designed as a probabilistic 
Markov model containing 200 different probability distributions. The model 
included eight health states; atrial fibrillation (AF), heart failure, moderate stroke 
sequela, severe stroke sequela, atrial fibrillation with previous AMI, atrial 
fibrillation with previous stroke, atrial fibrillation with major gastrointestinal 
bleeding and dead. Efficacy data was collected from a recently published report 
from the Canadian Health Technology Assessment Agency (CADTH). 
Epidemiological input data was gathered from registries. Data on Quality of Life 
were based on published EQ-5D data and costs were mainly based on national 
tariffs. The analysis was stratified according to risk of stroke as measured by 
CHA2DS2-VASc and risk of bleeding as measured by HAS-BLED. RESULTS: When 
the new drugs were compared relative to each other for medium risk patients, 
simulations indicated a 41% probability that apixaban is cost-effective, with 34% 
and 24% for dabigatran and rivaroxaban, respectively. For high risk patients, 
simulations indicated a 56% probability that dabigatran is cost-effective, with 
29% and 15% for apixaban and rivaroxaban, respectively. When comparing each 
of the new anticoagulants with the old (warfarin), analyses indicate a probability 
between 21% and 60% that warfarin is still cost-effective. In separate analyses, 
